Holen Sie sich die Stockscreener-App
92.32
3.96%
-3.10
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics stock hits all-time high at 96.65 USD - Investing.com Nigeria
Atika Capital Management LLC Takes $5.51 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
HC Wainwright raises Protagonist Therapeutics, Inc. (PTGX) target to $117, reiterates buy - MSN
Wall Street Recap: Is Protagonist Therapeutics Inc trading at a discount2026 Growth vs Value & Verified Swing Trading Watchlist - baoquankhu1.vn
PTGX: Two late-stage oral peptide drugs near approval, with strong pipeline and financial flexibility - TradingView
Protagonist Therapeutics (PTGX) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Responsive Playbooks and the PTGX Inflection - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month HighShould You Buy? - MarketBeat
Protagonist Therapeutics stock hits all-time high at 96.65 USD By Investing.com - Investing.com UK
Nasdaq Moves: Can Protagonist Therapeutics Inc expand into new markets2026 Market WrapUp & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Does FDA Priority Review For Rusfertide Transform The Bull Case For Protagonist Therapeutics (PTGX)? - Sahm
Intech Investment Management LLC Sells 12,310 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Sold by American Century Companies Inc. - MarketBeat
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - The Fayetteville Observer
Assessing Protagonist Therapeutics (PTGX) Valuation After Strong Recent Share Price Momentum - simplywall.st
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says - AOL.com
Is Protagonist Therapeutics (PTGX) Still Attractive After A 136% One Year Share Price Surge - simplywall.st
JPMorgan Chase & Co. Lowers Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics (PTGX) Target Price Raised by Goldman S - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $95.00 - MarketBeat
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Strong Buy Ratings and a Promising 14.42% Upside Potential - DirectorsTalk Interviews
TD Asset Management Inc Acquires 34,096 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating - marketscreener.com
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - lelezard.com
HC Wainwright Has Optimistic Outlook of PTGX Q1 Earnings - MarketBeat
Takeda Pharmaceutical and Protagonist Therapeutics Inc (NASDAQ: PTGX) jointly announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their co-developed drug Rusfertide and granted it prior - Bitget
Protagonist Therapeutics, Inc. $PTGX Shares Sold by Vanguard Group Inc. - MarketBeat
Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA Filing And Takeda Deal ShiftWhat's Changed - simplywall.st
Citigroup Inc. Has $10.14 Million Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift - Yahoo Finance
Protagonist Therapeutics (PTGX) Quarterly Loss Deepens To US$44.4m And Tests Bullish Profitability Narrative - Sahm
PTGX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance - AOL.com
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines - TipRanks
Understanding the Setup: (PTGX) and Scalable Risk - Stock Traders Daily
A Glimpse Into The Expert Outlook On Protagonist Therapeutics Through 8 Analysts - Benzinga
Protagonist Therapeutics (PTGX) Gets Price Target Lift from TD C - GuruFocus
TD Cowen Boosts Protagonist Therapeutics (NASDAQ:PTGX) Price Target to $100.00 - MarketBeat
PTGX: Today's Analyst Ratings and Price Target Updates | PTGX St - GuruFocus
Protagonist Therapeutics (PTGX) Sees Analyst Rating Update from Barclays | PTGX Stock News - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $113.00 at Barclays - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $112.00 - MarketBeat
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit - AOL.com
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Desert Sun
Citizens raises Protagonist Therapeutics stock price target on drug approvals By Investing.com - Investing.com Canada
Citizens raises Protagonist Therapeutics stock price target on drug approvals - Investing.com UK
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - The Register-Guard
Protagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Protagonist Therapeutics: Fourth Quarter Earnings Overview - Bitget
Protagonist Therapeutics: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - FinanzNachrichten.de
0.18%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):